Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, has announced that it has aligned with the U.S. Food and Drug Administration (FDA) to determine the appropriate dose of palazestrant for its pivotal clinical trials. The FDA has selected a 90 mg dose of palazestrant for both the Phase 3 OPERA-01 monotherapy trial and the Phase 3 OPERA-02 combination trial with ribociclib, focusing on ER+/HER2- metastatic breast cancer. This update will be presented at the upcoming American Society of Clinical Oncology (ASCO) Annual Meeting. The trials aim to address treatment resistance in metastatic breast cancer, and Olema anticipates top-line data from the OPERA-01 trial in 2026, with a potential commercial launch in 2027.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.